With the SPDR S&P Biotech Index up 30% over the trailing 12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in the sector last week.
Considering that we had the JPMorgan Healthcare Conference ongoing all week, there was absolutely no shortage of information and data being flung around by dozens of biotech companies. Since we've covered quite a few of the reporting companies and their presentations, here are a few of the more notable non-JPMorgan Conference stories that took center stage.
Peregrine Pharmaceuticals was one of the week's biggest gainers following a clarification of problems with its clinical study of bavituximab, a second-line treatment for non-small-cell lung cancer. Peregrine shares imploded a few months back, after the company warned investors not to rely on its clinical data, but ultimately it appears that only the 1mg/kg dose subset was affected. According to Peregrine, its 3mg/kg dose subset of patients survived roughly 13 months since beginning the treatment. While I'd hardly call Peregrine a sure thing following this third-party mishap, it's a step in the right direction.
Shares of biopharma giant Johnson & Johnson hardly budged this week, but it's worth noting that the FDA panel voted 10-5 in favor of recommending Invokana, its Type-2 diabetes SLGT-2 inhibitor, for approval. Although 10-5 isn't a ringing endorsement, and the FDA panel spent quite a bit of its review time contemplating the safety of Invokana on patients' hearts, this new type of inhibitor looks like it could capture quite a bit of the Type 2 diabetes market share if approved. As icing on the cake, J&J also received expanded approval in Europe to begin using its prostate cancer drug Zytiga earlier in the treatment process in combination with prednisone.
Although Novartis' Afinitor is already approved in the U.S. to treat kidney cancer, further clinical data published in The Lancet and highlighted by my Foolish colleague Dan Carroll demonstrates the effectiveness of the drug. According to data from the trial, Afinitor showed a significant reduction in kidney tumors due to tuberous sclerosis complex and exhibited a response rate of 42% versus 0% for the placebo.
On the other end of the spectrum, Merck announced yesterday that it'll pull its HDL cholesterol drug, Tredaptive, from market because it failed to reduce good cholesterol in patients and raised serious safety concerns in additional clinical trials. Although the side effects were non-fatal, they were still serious in nature, including blood, lymph, and gastrointestinal problems. Luckily for investors, Tredaptive, which is sold in 40 countries but isn't approved in the U.S., brought in only about $20 million in annual sales, so it won't be a big loss for Merck.
Finally, VIVUS shares took flight after the company noted that in its most recent rolling four-week period, it shipped approximately 13,000 orders for its fat-busting drug Qsymia. That's a clean 68% improvement over the previous four-week period, as the company announced that 14,500 people have now been treated with the drug. Clearly, Aetna and Express Scripts' coverage of Qsymia is helping push the cost out of patients' pockets and toward insurers, which is making a big difference in VIVUS' bottom-line results.
Cutting through the fat
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand-new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.
The article This Week in Biotech originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Express Scripts, as well as buying calls on Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.